Tags: Press release


LANXESS makes strong start to fiscal year 2022

In a challenging environment, specialty chemicals company LANXESS made a strong start to the year 2022. Today, it confirmed the preliminary figures for the first quarter released on April 19. LANXESS is also confident going into the second quarter, in which the Group expects EBITDA pre exceptionals of between EUR 280 million and EUR 350 million.

May 5, 2022


Womble Bond Dickinson Adds M&A Partner in Charlotte, N.C.

Womble Bond Dickinson announced today that Damian C. Georgino has joined the firm’s Corporate and Securities Group as a partner in the Charlotte, N.C. office. Damian advises U.S. and international corporations, including Fortune 50 companies, financial institutions, private equity funds, and other investors in complex transactions involving water and wastewater, energy, industrial/manufacturing, infrastructure, technology, and natural resource projects.

April 25, 2022

Cambrex Completes Large-Scale US API Expansion

Cambrex announced today the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex’s flagship API facility by 30%.

April 12, 2022

Pilot Chemical Becomes Exclusive Marketer of Integrity Bio-Chemicals’ Sustainable, High-Performance Biosurfactants in North American Markets

Pilot Chemical Corp. today announced an agreement with Integrity Bio-Chemicals (IBC) to be the exclusive marketer of IBC’s Tegrasurf TM line of high-performance biosurfactants into the North American Household, Industrial & Institutional (HI&I) markets. Tegrasurf TM products offer a substantial reduction in carbon footprint relative to many conventional surfactants while also exhibiting superior performance in foam stability and surface tension reduction.

April 4, 2022





Cambrex Expands Biopharmaceutical Services Business

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.

March 1, 2022